Catalent held a ground breaking ceremony at its Bloomington, IN site to mark the start of construction on a $112 million drug product manufacturing facility, which will increase fill/finish capacity in Bloomington by 79,000 square feet. The facility will house a high-speed vial line, utilizing both ready-to-use components and bulk filling; a high-speed flexible syringe/cartridge line; a fully automated vial inspection machine; and all associated services and support areas. Catalent Biologics plans to create up to 200 new jobs to support the increased production and completion of both construction and recruitment are expected by the end of 2024. Construction on the new facility is expected to be complete by June 2020.